News >

Expert Carefully Considers New Immunotherapy Combos in Nonsquamous NSCLC

Caroline Seymour
Published: Sunday, Jun 23, 2019

Jared Weiss, MD

Jared Weiss, MD
With the exception of the phase III KEYNOTE-042 trial, all of the pivotal phase III trials that have recently been reported in nonsquamous non–small cell lung cancer (NSCLC) have followed a similar formula by challenging the prior standard of care, chemotherapy, with the addition of a PD-1/PD-L1 inhibitor.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Therapies for Patients With ALK-Positive Lung Cancers: More Options…More Decisions…Better OutcomesAug 30, 20191.5
Oncology Briefings™: Treating Advanced NSCLC Without Actionable MutationsAug 30, 20191.0
Publication Bottom Border
Border Publication